THE VIVA FOUNDATION


Associated tags: Education, Vascular disease, Research, VIVA, Wynn Las Vegas, Medical imaging, Pharmaceutical industry, Blood vessel, Patient, Safety, Amputation, Freedom, Diabetes, DCB

Locations: NEVADA, NEW YORK

Final Round of Late-Breaking Clinical Trial Results Announced at VIVA23

Retrieved on: 
Wednesday, November 1, 2023
Female, Blood vessel, Maes, Kidney disease, Education, DCB, Freedom, MAE, TASC, Safety, Diabetes, Kaplan–Meier estimator, Research, Subgroup analysis, Meta-analysis, Pulmonary embolism, Death, BD, DVT, Detour, Clinical trial, Hypertension, Femoral vein, VIVA, TVR, Amputation, PTAB, Patient, Wynn Las Vegas, TLR, Medical imaging, Birth control, Pharmaceutical industry, Airline, SFA, Torus, EU

Below are highlights of this afternoon's 3 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this afternoon's 3 late-breaking clinical trial presentations.
  • A total of 1,005 patients at 74 investigational sites were treated with the Lutonix 035 DCB and were followed to 36 months.
  • Freedom from TLR at 12 months was 88.6%, and freedom from primary safety events at 30 days was 98.2%.
  • DETOUR clinical data demonstrate the clinical utility of this novel therapy in long femoropopliteal lesions.

Second Round of Late-Breaking Clinical Trial Results Announced at VIVA23

Retrieved on: 
Tuesday, October 31, 2023
Blood vessel, Patient, Angiography, Isabella Tree, Peripheral artery disease, PTA, De novo, Artery, Education, Incidence, DCB, Ioctl, BMI, AVF, CLTI, Kaplan–Meier estimator, Kidney disease, Research, HIV disease progression rates, RCT, Wound healing, BRS, Dialysis, Thrombosis, Clinical trial, Extremities, Risk, Dural arteriovenous fistula, Magnitude, Classification, VIVA, IVUS, Amputation, BTK, PAD, Wynn Las Vegas, Infection, Medical imaging, Pharmaceutical industry, Silviculture

Below are highlights of this afternoon's 3 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this afternoon's 3 late-breaking clinical trial presentations.
  • Results from Abbott's LIFE-BTK randomized clinical trial (RCT) demonstrate that Esprit BTK (Abbott) reduces disease progression and helps improve medical outcomes compared to balloon angioplasty, the current state of care.
  • In the LIFE-BTK trial, wound assessment was not a prespecified powered primary or secondary endpoint but rather a prespecified descriptive endpoint.
  • The trial offers the largest ischemic wound data set to date, collected systematically and adjudicated independently in a blinded fashion.

First Round of Late-Breaking Clinical Trial Results Announced at VIVA23

Retrieved on: 
Tuesday, October 31, 2023
Atheroma, Peripheral artery disease, Diabetes, Pivotal trial, Ulcer, Transducer, Male, Disease, PAP, Buerger's test, Classification, The Unreconstructed M, IVUS, Amputation, Stent, PAD, PP, Thorpe tube flowmeter, TUS, Calf, Chin Na, Vein, Telephone, TASC, Bare, Vibrato, Life, SP, W. L. Gore & Associates, VIVA, Safety, Patient, Dyslipidemia, Blood vessel, Plaque, History, CLTI, Coronary artery disease, Perfusion, Restenosis, Research, Foot, Spur, Atherectomy, Șaeș, Artery, Education, DCB, Doppler effect, Dialysis, Hypertension, FP, Freedom, Wynn Las Vegas, Wound healing, Medical imaging, Pharmaceutical industry, Birth control, Surveying, Medtronic

Below are highlights of this morning's 5 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this morning's 5 late-breaking clinical trial presentations.
  • At 20 centers without roll-ins across the United States, 105 no-option CLTI patients were enrolled in a nonrandomized manner.
  • The median age was 70 years, two-thirds of the patients were male, and one-quarter of patients were Hispanic or Latino.
  • 1-Year Results of the DEEPER OUS Trial: The Bare Temporary Spur Stent System in Combination With a Paclitaxel-Coated Balloon
    The DEEPER OUS trial is a prospective, nonrandomized, multicenter, single-arm trial taking place in New Zealand, Germany, and Switzerland.

Late-Breaking Clinical Trial Results Announced at The VEINS 2023

Retrieved on: 
Monday, October 30, 2023
Trial of the century, RCT, Male, The, Thrombolysis, Dexamethasone, VIVID, PE, DVT, Hemodynamics, BPM, Deep vein thrombosis, PTS, VIVA, Safety, Patient, Ageing, Contraindication, Heart rate, CTA, Research, Quality of life, Syndrome, Anesthesia, Education, Villalta, USP, Freedom, Randomized controlled trial, Wynn Las Vegas, Birth control, Medical imaging, Pharmaceutical industry, Akura, Bullfrog

Below are highlights of this morning's 4 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this morning's 4 late-breaking clinical trial presentations.
  • These favorable clinical outcomes highlight the need for randomized controlled trial data comparing MT with standard of care anticoagulation treatment.
  • In the second phase of the trial, 60 participants will be enrolled 1:1 in a dual-blinded, randomized controlled trial (RCT).
  • Of the 21 patients followed at 1 month, 19 (90.5%) had fully compressible and two had partially compressible common femoral veins.

First-on-Podium Data from 20 Vascular and Venous Clinical Trials to Be Presented at The VEINS and VIVA 2023

Retrieved on: 
Wednesday, August 30, 2023
Learning, Wynn Las Vegas, Atherectomy, Subgroup analysis, Pivotal trial, Perfusion, VIVA, Bare, Physician, Vein, Blood vessel, Diagnosis, Patient, Moyamoya disease, Nursing, Birth control, Medical imaging

PALM SPRINGS, Calif., Aug. 30, 2023 /PRNewswire/ -- Leading physicians and researchers will present results from 20 clinical trials from Monday, October 30, to Wednesday, November 1, at the annual VIVA and The VEINS conferences at Wynn Las Vegas.

Key Points: 
  • PALM SPRINGS, Calif., Aug. 30, 2023 /PRNewswire/ -- Leading physicians and researchers will present results from 20 clinical trials from Monday, October 30, to Wednesday, November 1, at the annual VIVA and The VEINS conferences at Wynn Las Vegas.
  • VIVA (Vascular InterVentional Advances) is a vascular education symposium that emphasizes innovation and multidisciplinary learning.
  • The 2023 conference will mark VIVA's 21st anniversary as a premier educational event for peripheral vascular disease specialists.
  • The VEINS (Venous Endovascular INterventional Strategies) is a comprehensive symposium focused on the diagnosis, intervention, and management of venous disorders.

Final Round of Late-Breaking Clinical Trial Results Announced at VIVA22

Retrieved on: 
Wednesday, November 2, 2022

Below are summaries of this morning's 5 late-breaking clinical trial presentations.

Key Points: 
  • Below are summaries of this morning's 5 late-breaking clinical trial presentations.
  • In summary, all four devices were effective for preventing aneurysm rupture and aneurysm-related death in over 97% of patients out to 5 years.
  • 70% of patients were still alive at 5 years, and thus further follow-up will be necessary to determine long-term outcomes.
  • These results demonstrate the ability of the SVS VQI to conduct postmarket evaluation of peripheral devices in partnership with industry and federal regulators.

Second Round of Late-Breaking Clinical Trial Results Announced at VIVA22

Retrieved on: 
Wednesday, November 2, 2022

Below are summaries of this afternoon's 6 late-breaking clinical trial presentations.

Key Points: 
  • Below are summaries of this afternoon's 6 late-breaking clinical trial presentations.
  • RELINE MAX was a prospective, single-arm international study that enrolled patients at 23 sites from October 2015 to April 2018.
  • Patients with 50% ISR or occlusion in the SFA, Rutherford category 2-5 disease, and 1 patent runoff vessel were eligible.
  • PROMISE II is a pivotal trial of the LimFlow system for transcatheter arterialization of the deep veins (TADV) (LimFlow, Inc.).

First Round of Late-Breaking Clinical Trial Results Announced at VIVA22

Retrieved on: 
Tuesday, November 1, 2022

Below are highlights of this morning's 5 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this morning's 5 late-breaking clinical trial presentations.
  • DCBs and BMSs were compared using the inverse probability of treatment weight (IPTW) method with weighted log-rank P values.
  • The results of this analysis support the primary use of DCB versus BMS in moderately complex femoropopliteal lesions, with superior effectiveness and no differences in mortality, amputation, or thrombosis.
  • K-M primary patency at 24 months was 70.8% for SurVeil DCB versus 70.4% for IN.PACT Admiral DCB (log rank P = .991).

First-Ever Late-Breaking Clinical Trial Results Announced at The VEINS 2022

Retrieved on: 
Monday, October 31, 2022

Below are highlights of this morning's 6 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this morning's 6 late-breaking clinical trial presentations.
  • Mean EuroQoL five dimensions index QOL and VEINES-QOL scores improved from baseline for all initial clinical presentations.
  • The mean Villalta score in the target limb and mean Venous Clinical Severity Score decreased from baseline to 36 months for all initial clinical presentations.
  • Small vein diameter strongly correlates with maturation failure; 6-mm veins have a 75% probability of maturation versus 10% for 3-mm veins.

First-on-Podium Data from 21 Vascular Interventional Clinical Trials to Be Presented at The VEINS and VIVA 2022

Retrieved on: 
Thursday, September 1, 2022
Treatment, Wynn Las Vegas, Research, Virtual, Awareness, Health and Quality of Life Outcomes, Subgroup analysis, Vascular disease, Physician, Diagnosis, Education, Multimedia, Human, STRIDE, Disrupt, Multicenter trial, Observational study, Blood vessel, VIVA, Lithotripsy, Pharmaceutical industry, Medicine, Medical imaging

VIVA (Vascular InterVentional Advances) is a vascular education symposium that emphasizes innovation and multidisciplinary learning.

Key Points: 
  • VIVA (Vascular InterVentional Advances) is a vascular education symposium that emphasizes innovation and multidisciplinary learning.
  • The VEINS (Venous Endovascular INterventional Strategies) is a comprehensive education symposium focused on the diagnosis, intervention, and management of venous disorders.
  • VIVA and The VEINS bring together a global, multispecialty faculty to present a variety of talks and live case presentations from clinical centers around the world.
  • Attendees for both events include an audience of interventional cardiologists, interventional radiologists, vascular surgeons, and endovascular medicine specialists.